{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:20:41Z","timestamp":1787019641094,"version":"build-2736575974"},"reference-count":44,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,12,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Monoclonal gammopathy of undetermined significance (MGUS) is a highly prevalent disorder characterized by a small bone marrow plasma cell or lymphoplasmacytic clone (less than 10%) that produces a small amount of monoclonal paraprotein without associated organ damage. Most patients with MGUS display benign behavior indefinitely, but some progress to an overt malignancy, and others develop organ damage despite no increase in monoclonal protein, resulting in the so-called MG of clinical significance (MGCS). This concept includes different disorders depending on the organ involved, and among them, MG of neurological significance (MGNS) constitutes a real challenge from both a diagnostic and therapeutic point of view. Diagnosis is particularly difficult due to MGNS's heterogeneous clinical presentation and common lack of a diagnostic biopsy. On the other hand, the complexity of treatment lies in the lack of standardized regimens and the common irreversibility of neurological damage. Focusing on the neurological manifestations of MGUS affecting the peripheral nervous system, we describe 3 illustrative cases from daily practice and discuss different aspects of diagnosis to treatment, emphasizing the need for multidisciplinary management based on the close collaboration of neurologists and hematologists.<\/jats:p>","DOI":"10.1182\/hematology.2024000665","type":"journal-article","created":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T10:04:51Z","timestamp":1733479491000},"page":"499-504","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":9,"title":["Neurological manifestations of MGUS"],"prefix":"10.1182","volume":"2024","author":[{"given":"M. Teresa","family":"Cibeira","sequence":"first","affiliation":[{"name":"1 Hematology Department, Amyloid and Myeloma Unit, Hospital Cl\u00ednic de Barcelona and Institut d\u00b4Investigacions Biom\u00e8diques August Pi I Sunyer, University of Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis Gerardo","family":"Rodr\u00edguez-Lobato","sequence":"additional","affiliation":[{"name":"1 Hematology Department, Amyloid and Myeloma Unit, Hospital Cl\u00ednic de Barcelona and Institut d\u00b4Investigacions Biom\u00e8diques August Pi I Sunyer, University of Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aida","family":"Alejaldre","sequence":"additional","affiliation":[{"name":"2 Neurology Department, Amyloid and Myeloma Unit, Hospital Cl\u00ednic de Barcelona and Institut d\u00b4Investigacions Biom\u00e8diques August Pi I Sunyer, University of Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Fern\u00e1ndez de Larrea","sequence":"additional","affiliation":[{"name":"1 Hematology Department, Amyloid and Myeloma Unit, Hospital Cl\u00ednic de Barcelona and Institut d\u00b4Investigacions Biom\u00e8diques August Pi I Sunyer, University of Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,12,6]]},"reference":[{"issue":"12","key":"2024121115510863700_hem2024000665C1","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"issue":"11","key":"2024121115510863700_hem2024000665C2","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1182\/blood.2022015851","article-title":"The International Consensus Classification of mature lymphoid neoplasms: a report from the Clinical Advisory Committee","volume":"140","author":"Campo","year":"2022","journal-title":"Blood"},{"issue":"14","key":"2024121115510863700_hem2024000665C3","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1182\/blood-2018-04-839480","article-title":"Monoclonal gammopathy of clinical significance: a novel concept with therapeutic implications","volume":"132","author":"Fermand","year":"2018","journal-title":"Blood"},{"issue":"6","key":"2024121115510863700_hem2024000665C4","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.3390\/cancers14061562","article-title":"From biology to treatment of monoclonal gammopathies of neurological significance","volume":"14","author":"Visentin","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"1","key":"2024121115510863700_hem2024000665C5","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41581-018-0077-4","article-title":"The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group","volume":"15","author":"Leung","year":"2019","journal-title":"Nat Rev Nephrol"},{"issue":"20","key":"2024121115510863700_hem2024000665C6","doi-asserted-by":"crossref","first-page":"5131","DOI":"10.3390\/cancers13205131","article-title":"Treatment of patients with monoclonal gammopathy of clinical significance","volume":"13","author":"Moreno","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"11","key":"2024121115510863700_hem2024000665C7","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1212\/WNL.31.11.1480","article-title":"Prevalence of monoclonal protein in peripheral neuropathy","volume":"31","author":"Kelly","year":"1981","journal-title":"Neurology"},{"issue":"7","key":"2024121115510863700_hem2024000665C8","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1002\/ajh.26155","article-title":"The evaluation and management of monoclonal gammopathy of renal significance and monoclonal gammopathy of neurological significance","volume":"96","author":"Castillo","year":"2021","journal-title":"Am J Hematol"},{"issue":"2","key":"2024121115510863700_hem2024000665C9","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/mus.28164","article-title":"Paraproteinemic neuropathies","volume":"70","author":"Traub","year":"2024","journal-title":"Muscle Nerve"},{"issue":"11","key":"2024121115510863700_hem2024000665C10","doi-asserted-by":"crossref","first-page":"2679","DOI":"10.3324\/haematol.2019.239632","article-title":"Peripheral neuropathy and monoclonal gammopathy of undetermined significance: a population-based study including 15,351 cases and 58,619 matched controls","volume":"105","author":"R\u00f6gnvaldsson","year":"2020","journal-title":"Haematologica"},{"issue":"5","key":"2024121115510863700_hem2024000665C11","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1111\/bjh.14492","article-title":"Investigation and management of IgM and Waldenstr\u00f6m-associated peripheral neuropathies: recommendations from the IWWM-8 Consensus Panel","volume":"176","author":"D'Sa","year":"2017","journal-title":"Br J Haematol"},{"issue":"9","key":"2024121115510863700_hem2024000665C12","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.3324\/haematol.2022.280953","article-title":"IgM monoclonal gammopathies of clinical significance: diagnosis and management","volume":"107","author":"Khwaja","year":"2022","journal-title":"Haematologica"},{"issue":"9","key":"2024121115510863700_hem2024000665C13","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1136\/jnnp-2017-316689","article-title":"High prevalence of the MYD88 L265P mutation in IgM anti-MAG paraprotein-associated peripheral neuropathy","volume":"89","author":"Vos","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"8","key":"2024121115510863700_hem2024000665C14","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1007\/s00415-019-09367-0","article-title":"Relevance of anti-HNK1 antibodies in the management of anti-MAG neuropathies","volume":"266","author":"Delmont","year":"2019","journal-title":"J Neurol"},{"key":"2024121115510863700_hem2024000665C15","first-page":"14","article-title":"A novel cell-based immunofluorescence assay for the detection of autoantibodies to myelin-associated glycoprotein","author":"Mariotto","year":"2023","journal-title":"Front Neurol"},{"issue":"pt 10","key":"2024121115510863700_hem2024000665C16","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1093\/brain\/124.10.1968","article-title":"The clinical and laboratory features of chronic sensory ataxic neuropathy with anti-disialosyl IgM antibodies","volume":"124","author":"Willison","year":"2001","journal-title":"Brain"},{"issue":"1","key":"2024121115510863700_hem2024000665C17","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/(SICI)1097-4598(200001)23:1<73::AID-MUS9>3.0.CO;2-5","article-title":"Diagnostic criteria for demyelinating polyneuropathy associated with monoclonal gammopathy","volume":"23","author":"Notermans","year":"2000","journal-title":"Muscle Nerve"},{"key":"2024121115510863700_hem2024000665C18","first-page":"11","article-title":"Advances in the diagnosis, immunopathogenesis and therapies of IgM-anti-MAG antibody-mediated neuropathies","author":"Dakalas","year":"2018","journal-title":"Ther Adv Neurol Disord"},{"issue":"3","key":"2024121115510863700_hem2024000665C19","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1002\/ana.21577","article-title":"Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein antibody demyelinating neuropathy","volume":"65","author":"Dalakas","year":"2009","journal-title":"Ann Neurol"},{"issue":"24","key":"2024121115510863700_hem2024000665C20","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1212\/WNL.0b013e318296e92b","article-title":"Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein neuropathy","volume":"80","author":"L\u00e9ger","year":"2013","journal-title":"Neurology"},{"issue":"10","key":"2024121115510863700_hem2024000665C21","first-page":"CD002827","article-title":"Immunotherapy for IgM anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathies","volume":"10","author":"Lunn","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"issue":"12","key":"2024121115510863700_hem2024000665C22","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s11940-017-0479-9","article-title":"Advances in the treatment of paraproteinemic neuropathy","volume":"19","author":"Nobile-Orazio","year":"2017","journal-title":"Curr Treat Options Neurol"},{"issue":"1","key":"2024121115510863700_hem2024000665C23","doi-asserted-by":"crossref","first-page":"302","DOI":"10.3324\/haematol.2019.243139","article-title":"Chemoimmunotherapy with rituximab, cyclophosphamide and prednisolone in IgM paraproteinaemic neuropathy: evidence of sustained improvement in electrophysiological, serological and functional outcomes","volume":"106","author":"Colchester","year":"2021","journal-title":"Haematologica"},{"issue":"15","key":"2024121115510863700_hem2024000665C24","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1501548","article-title":"Ibrutinib in previously treated Waldenstr\u00f6m's macroglobulinemia","volume":"372","author":"Treon","year":"2015","journal-title":"N Engl J Med"},{"issue":"4","key":"2024121115510863700_hem2024000665C25","doi-asserted-by":"crossref","first-page":"e720","DOI":"10.1212\/NXI.0000000000000720","article-title":"The Bruton tyrosine kinase inhibitor ibrutinib improves anti-MAG antibody polyneuropathy","volume":"7","author":"Castellani","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"suppl 1","key":"2024121115510863700_hem2024000665C26","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1182\/blood-2023-185113","article-title":"Prospective study of acalabrutinib with rituximab in patients with symptomatic anti-MAG mediated IgM peripheral neuropathy","volume":"142","author":"Sarosiek","year":"2023","journal-title":"Blood"},{"issue":"3","key":"2024121115510863700_hem2024000665C27","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1212\/WNL.54.3.615","article-title":"Distal acquired demyelinating symmetric neuropathy","volume":"54","author":"Katz","year":"2000","journal-title":"Neurology"},{"issue":"5","key":"2024121115510863700_hem2024000665C28","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.mayocp.2017.02.003","article-title":"Monoclonal gammopathy-associated peripheral neuropathy: diagnosis and management","volume":"92","author":"Chaudhry","year":"2017","journal-title":"Mayo Clin Proc"},{"issue":"4","key":"2024121115510863700_hem2024000665C29","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1097\/00005792-198007000-00006","article-title":"Plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, M-protein and skin changes: the POEMS syndrome","volume":"59","author":"Bardwick","year":"1980","journal-title":"Medicine (Baltimore)"},{"issue":"5","key":"2024121115510863700_hem2024000665C30","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1136\/jnnp-2011-301472","article-title":"Uniform demyelination and more severe axonal loss distinguish POEMS syndrome from CIDP","volume":"83","author":"Mauermann","year":"2012","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"7","key":"2024121115510863700_hem2024000665C31","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1182\/blood-2002-07-2299","article-title":"POEMS syndrome: definitions and long-term outcome","volume":"101","author":"Dispenzieri","year":"2003","journal-title":"Blood"},{"issue":"12","key":"2024121115510863700_hem2024000665C32","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1002\/ajh.27081","article-title":"POEMS syndrome: update on diagnosis, risk-stratification, and management","volume":"98","author":"Dispenzieri","year":"2023","journal-title":"Am J Hematol"},{"issue":"1","key":"2024121115510863700_hem2024000665C33","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1182\/blood-2013-03-487025","article-title":"Outcomes of patients with POEMS syndrome treated initially with radiation","volume":"122","author":"Humeniuk","year":"2013","journal-title":"Blood"},{"issue":"1","key":"2024121115510863700_hem2024000665C34","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1182\/blood-2012-04-423178","article-title":"Long-term outcomes after autologous stem cell transplantation for patients with POEMS syndrome (osteosclerotic myeloma): a single-center experience","volume":"120","author":"D'Souza","year":"2012","journal-title":"Blood"},{"issue":"1","key":"2024121115510863700_hem2024000665C35","doi-asserted-by":"crossref","first-page":"160","DOI":"10.3324\/haematol.2016.148460","article-title":"High-dose therapy and autologous stem cell transplantation in patients with POEMS syndrome: a retrospective study of the Plasma Cell Disorder Sub-committee of the Chronic Malignancy Working Party of the European Society for Blood & Marrow Transplantation","volume":"102","author":"Cook","year":"2017","journal-title":"Haematologica"},{"issue":"4","key":"2024121115510863700_hem2024000665C36","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1038\/s41375-019-0391-2","article-title":"What is the best first-line treatment for POEMS syndrome: autologous transplantation, melphalan and dexamethasone, or lenalidomide and dexamethasone?","volume":"33","author":"Zhao","year":"2019","journal-title":"Leukemia"},{"issue":"6","key":"2024121115510863700_hem2024000665C37","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1002\/ajh.25100","article-title":"A prospective phase II study of low dose lenalidomide plus dexamethasone in patients with newly diagnosed polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes (POEMS) syndrome","volume":"93","author":"Li","year":"2018","journal-title":"Am J Hematol"},{"issue":"3","key":"2024121115510863700_hem2024000665C38","doi-asserted-by":"crossref","first-page":"e381","DOI":"10.1097\/HS9.0000000000000381","article-title":"Upfront daratumumab with lenalidomide and dexamethasone for POEMS syndrome","volume":"4","author":"Gavriatopoulou","year":"2020","journal-title":"Hemasphere"},{"issue":"11","key":"2024121115510863700_hem2024000665C39","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1136\/jnnp.2007.116368","article-title":"Complications following sural and peroneal nerve biopsies","volume":"78","author":"Hilton","year":"2007","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"2024121115510863700_hem2024000665C40","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1080\/13506129.2022.2093635","article-title":"Guidelines for non-transplant chemotherapy for treatment of systemic AL amyloidosis: EHA-ISA Working Group","volume":"30","author":"Wechalekar","year":"2023","journal-title":"Amyloid"},{"issue":"1","key":"2024121115510863700_hem2024000665C41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/13506129.2021.2002841","article-title":"Guidelines for high dose chemotherapy and stem cell transplantation for systemic AL amyloidosis: EHA-ISA Working Group guidelines","volume":"29","author":"Sanchorawala","year":"2022","journal-title":"Amyloid"},{"issue":"4","key":"2024121115510863700_hem2024000665C42","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1529-8027.2010.00290.x","article-title":"European Federation of Neurological Societies\/Peripheral Nerve Society guideline on management of multifocal motor neuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society\u2014first revision","volume":"15","author":"Van Schaik","year":"2010","journal-title":"J Peripher Nerv Syst"},{"issue":"1","key":"2024121115510863700_hem2024000665C43","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1212\/WNL.0000000000013038","article-title":"Oral and topical treatment of painful diabetic polyneuropathy: practice guideline update summary. Report of the AAN Guideline Subcommittee","volume":"98","author":"Price","year":"2022","journal-title":"Neurology"},{"issue":"5","key":"2024121115510863700_hem2024000665C44","first-page":"1492","article-title":"Paraproteinemic neuropathies","volume":"29","author":"Beydoun","year":"2023","journal-title":"Continuum (Minneapolis)"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2024\/1\/499\/2346763\/499cibeira.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2024\/1\/499\/2346763\/499cibeira.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T15:26:26Z","timestamp":1733930786000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2024\/1\/499\/526243\/Neurological-manifestations-of-MGUS"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,6]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12,6]]},"published-print":{"date-parts":[[2024,12,6]]}},"URL":"https:\/\/doi.org\/10.1182\/hematology.2024000665","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,12,6]]},"published":{"date-parts":[[2024,12,6]]}}}